Itema, leading global provider of advanced weaving solutions, and Tofflon Science and Technology Group Co. Ltd., Asiatic giant company in the pharmaceutical industry, have presented Tofflonit, the new joint venture dedicated to the production of industrial lyophilizers for the biopharmaceutical sector that operates under the name Tofflon Itema Srl. With an initial investment of 10 million euros, the company will have its regional headquarters in Nibbia, in the province of Novara, where a manufacturing plant with high quality and innovation levels has been operating since October. The agreement was illustrated in Bergamo on October 24th during BioTopics 2023, the event dedicated to biotechnologies and open innovation.

Founded in Shanghai in 1993, Tofflon is a comprehensive pharmaceutical equipment supplier to provide process support, core equipment, integrated system and pharma engineering for the pharma and biotech industry, with more than 5,800 employees worldwide and a 2022 turnover of about 800 million US dollars. In order to pursue its strategy of internationalization and expansion, the group chose Itema as the partner for the planning and engineering of its new branch in Europe, where the group will produce lyophilization systems for the production of antibiotics, vaccines, diagnostic drugs, products containing proteins and biotechnological products.

“Throughout our thirty-year activity, we have developed solid skills for the production of machinery and equipment for the pharmaceutical and biotech industry. Our aim is to further grow in the European and American markets, approaching clients to whom we want to ensure the excellence of our solutions with efficient services and ideal shipping times. We are sure that the collaboration with Itema will enable us to reach excellent results”, said Michael Chang, senior vice president of Tofflon Science and Technology Group Co. Ltd.